| |
Cohort I
|
Cohort II
|
|---|
|
Characteristic
|
Low ANLN NF n (%)
|
High ANLN NF n (%)
|
p-value
|
Low ANLN NF n (%)
|
High ANLN NF n (%)
|
p-value
|
|---|
|
Age (years)
|
|
≤ median
|
42 (67.7)
|
20 (32.3)
| |
138 (68.0)
|
65 (32.0)
| |
|
> median
|
32 (50.0)
|
32 (50.0)
|
0.043
|
110 (71.0)
|
45 (29.0)
|
0.544
|
|
Tumor size (mm)
|
|
≤ 20
|
42 (72.4)
|
16 (27.6)
| |
99 (76.7)
|
30 (23.3)
| |
|
> 20
|
32 (47.1)
|
36 (52.9)
|
0.004
|
149 (65.1)
|
80 (34.9)
|
0.021
|
|
ER status
|
|
Negative
|
6 (31.6)
|
13 (68.4)
| |
50 (43.9)
|
64 (56.1)
| |
|
Positive
|
68 (63.6)
|
39 (36.4)
|
0.009
|
191 (81.6)
|
43 (18.4)
|
<0.001
|
|
PR status
|
|
Negative
|
15 (39.5)
|
23 (60.5)
| |
46 (40.7)
|
67 (59.3)
| |
|
Positive
|
59 (67.0)
|
29 (33.0)
|
0.004
|
188 (82.5)
|
40 (17.5)
|
<0.001
|
|
Grade (NHG)
|
|
I
|
16 (100.0)
|
0 (0.0)
| |
36 (97.3)
|
1 (2.7)
| |
|
II
|
43 (74.1)
|
15 (25.9)
| |
130 (86.7)
|
20 (13.3)
| |
|
III
|
15 (28.8)
|
37 (71.2)
|
<0.001
|
76 (47.2)
|
85 (52.8)
|
<0.001
|
|
Nodal status
|
|
Negative
|
41 (63.1)
|
24 (36.9)
| |
64 (66.0)
|
33 (34.0)
| |
|
Positive
|
25 (49.0)
|
26 (51.0)
|
0.129
|
183 (70.4)
|
77 (29.6)
|
0.423
|
|
Ki-67
|
|
≤ 10%
|
50 (96.2)
|
2 (3.8)
| |
101 (91.8)
|
9 (8.2)
| |
|
> 10%
|
22 (30.6)
|
50 (69.4)
|
<0.001
|
142 (59.4)
|
97 (40.6)
|
<0.001
|
|
HER2 status
|
|
0–2+
|
72 (61.5)
|
45 (38.5)
| |
193 (70.4)
|
81 (29.6)
| |
|
3+
|
2 (22.2)
|
7 (77.8)
|
0.021
|
28 (58.3)
|
20 (41.7)
|
0.095
|
-
ER estrogen receptor, PR progesterone receptor, NHG Nottingham histological grade, HER2 human epidermal growth factor receptor 2
- Age was defined as years at diagnosis. Positive ER and PR expression was considered as >10%. Chi square test, linear-by-linear test or Fisher’s exact test were used to test the significance between groups. Significant correlations (p < 0.05) are indicated by bold numbers
